Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression.
Primary Care Companion J Clin Psychiatry 2001;3(1):10-16
© Copyright 2015 Physicians Postgraduate Press, Inc.
Background: This open-label portion of a
2-phase study assessed the effects of the antidepressant
bupropion sustained release (SR) on health-related quality of
life (QOL) and workplace productivity in patients with major
Method: Patients (N = 816) with DSM-IV
major depression were treated with bupropion SR, 300 mg/day, for
8 weeks. The Clinical Global Impressions scale for Improvement of
Illness (CGI-I) was completed at weekly clinic visits. At
baseline and week 8, QOL and productivity were assessed. QOL was
assessed using the Quality of Life in Depression Scale (QLDS).
Results: QOL and productivity were
significantly improved from baseline after 8 weeks of treatment
with bupropion SR. Mean QLDS scores were 18.98 and 10.36 at
baseline and week 8, respectively (mean change = 8.62; p <
.001). At week 8 compared with baseline, patients working at a
paid job reported missing 1.58 fewer hours of work because of
depression during the past 7 days, being 14.6% more effective on
the job, working at reduced effectiveness less often, and
incurring 6.37 fewer hours of overall lost productivity (p <
.001 each variable). Improvements in QOL and productivity were
significantly (p < .001) greater in bupropion SR responders
(i.e., those with CGI-I scores of "very much improved"
or "much improved" during the last 3 weeks of
open-label therapy) than in nonresponders.
Conclusion: Effective treatment of major
depression with bupropion SR for 8 weeks is associated with
improvements in QOL and reductions in lost workplace
productivity. Patients who responded clinically to bupropion SR
showed significantly greater improvements in these variables than
those who did not respond.